References
- Barbacid M. RAS genes. Annu Rev Biochem 1987;56:779–82
- Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11–22
- Aoki Y, Niihori T, Kawame H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Gene 2005;37:1038–40
- Zenker M, Lehmann K, Schulz AL, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2006;44:131–5
- Roberts AE, Araki T, Swanson KD, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007;39:70–4
- Tartaglia M, Pennacchio LA, Zhao CY. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75–9
- Narumi Y, Aoki Y, Niihori T, et al. Clinical manifestations in patients with SOS1 mutations range from Noonan syndrome to CFC syndrome. J Hum Genet 2008;53:834–41
- Boriack-Sjodin PA, Margarit SM, Bar-Sagi D, Kuriyan J. The structural basis of the activation of Ras by Sos. Nature 1998;394:337–43
- Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–25
- Lepri F, De Luca A, Stella L, et al. SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations. Hum Mut 2011;32:760–72
- Chen PC, Wakimoto H, Conner D, et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 2010;120:4353–65
- Tumurkhuu M, Saitoh M, Sato A, et al. A comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway. Pediatr Int 2010;52:557–62
- Sondermann H, Soisson SM, Bar-Sagi D, Kuriyan J. Tandem histone folds in the structure of the N-terminal segment of the RAS activator Son of Sevenless. Structure 2003;11:1583–93
- Sondermann H, Soisson SM, Boykevicsh M, et al. Structural analysis of autoinhibition in the RAS activator Son of Sevenless. Cell 2004;119:393–405
- Bilanges B, Vanhaesebroeck B. A new tool to dissect the function of p70 S6 kinase. Biochem J 2011;431:e1–3
- Harrington LS, Findlay GM, Gray A, et al. The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins. J Cell Biol 2004;166:213–23
- Pullen N, Dennis PB, Andjelkovic M, et al. Phosphorylation and activation of p70s6k by PDK1. Science 1998;279:707–10
- Dennis PB, Pullen N, Pearson RB, et al. Phosphorylation sites in the autoinhibitory domain participate in p70S6K activation loop phosphorylation. J Biol Chem 1998;273:14845–52
- Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010;141:1117–34
- Albert R. Scale-free networks in cell biology. J Cell Sci 2005;118:4947–57
- Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004;5:101–13
- Chen JY, Lin JR, Cimprich KA, Meyer T. A two-dimensional ERK-AKT signaling code for an NGF-triggered cell-fate decision. Mol Cell 2012;45:196–209
- Ko JM, Kim JM, Kim GH, Yoo HW. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 2008;53:999–1006